Ocular Patents (Class 424/427)
-
Patent number: 8647658Abstract: The present invention relates to improved contact lens products which not only have initial insertion comfort but also are comfortable to wear for more than about 6 hours. The invention is achieved by packaging and storing a hydrogel lens with two or more leachable polymeric lubricants incorporated therein in a relatively viscous packaging solution including a relatively low molecular weight polyethylene glycol (PEG) and a viscosity-enhancing hydrophilic polymer. The present invention also provides methods for making contact lens products of the invention.Type: GrantFiled: August 27, 2008Date of Patent: February 11, 2014Assignee: Novartis AGInventors: John Dallas Pruitt, Lynn Cook Winterton
-
Patent number: 8642066Abstract: Disclosed is a drug delivery system for delivering a drug at a sustained constant rate for a long period, which can be transplanted into an affected part safely and in a simple manner and can deliver a drug to the affected part for a long period. Specifically disclosed is a sustained drug delivery system in which an implant is implanted into a body, wherein the implant is a PEG capsule comprising a box-shaped PEG and a porous PEG sheet.Type: GrantFiled: February 16, 2012Date of Patent: February 4, 2014Assignee: Tohoku UniversityInventors: Toshiaki Abe, Nobuhiro Nagai, Hirokazu Kaji, Takeaki Kawashima, Matsuhiko Nishizawa, Koji Nishida
-
Patent number: 8637070Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.Type: GrantFiled: February 9, 2006Date of Patent: January 28, 2014Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
-
Patent number: 8628572Abstract: Provided herein is an endothelial scaffold comprising, consisting of, or consisting essentially of decellularized corneal stroma. In some embodiments, the scaffold has cultured endothelial cells seeded thereon. Methods of treating a patient in need of corneal endothelial transplant are also provided, including implanting the scaffold as described herein onto a cornea of the patient (e.g., by deep keratectomy).Type: GrantFiled: February 25, 2010Date of Patent: January 14, 2014Assignee: Wake Forest University Health SciencesInventors: Shay Soker, J. Koudy Williams, Patrick Laber, Margaret Greven, Keith A. Walter
-
Patent number: 8623400Abstract: The present invention discloses a drug-carrying contact lens and a method for fabricating the same. The drug-carrying contact lens comprises a contact lens containing at least one amphiphatic hybrid nanocarrier carrying drug molecules. According to the heat or light sensitivity of the drug molecule, the present invention respectively fabricates an encapsulation-type drug-carrying contact lens and a drug-soaking type drug-carrying contact lens. The present invention uses a highly-biocompatible amphiphatic hybrid nanocarriers having superior drug encapsulation capability to wrap the drug molecules. Thereby, the drug molecules are uniformly distributed in the contact lens and can be gradually and locally released to the eye of the user wearing the contact lens. Therefore, the present invention can prevent or cure ocular diseases with the loss and side effects of the drug being reduced.Type: GrantFiled: October 7, 2011Date of Patent: January 7, 2014Assignee: National Chiao Tung UniversityInventors: Dean-Mo Liu, Pei-Ling Liu
-
Patent number: 8609634Abstract: The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium chloride (BAK).Type: GrantFiled: May 16, 2007Date of Patent: December 17, 2013Assignee: McNeil-PPC, Inc.Inventors: Uday Doshi, Kenneth T. Holeva
-
Patent number: 8603522Abstract: A daily nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The ingredients of the daily nutritional or dietary supplement composition include vitamin C, vitamin E, lutein, zinc and copper. The ingredients are preferably provided in a tablet form suitable for oral ingestion.Type: GrantFiled: January 13, 2005Date of Patent: December 10, 2013Assignee: Bausch & Lomb IncorporatedInventors: Stephen Paul Bartels, Cara Larraine Baustian, George Edwin Bunce, Leon Ellenbogen, Frederick L. Ferris, III, Jin Kinoshita, James Cecil Smith, Jr., David A. Souerwine
-
Patent number: 8580565Abstract: The present invention relates to a device and methods for culturing stem cells, and in particular, for culturing ocular stem cells and the use of stem cells cultured using the devices and methods of the invention for the treatment of diseases.Type: GrantFiled: December 6, 2010Date of Patent: November 12, 2013Inventor: Minas Theodore Coroneo
-
Patent number: 8574613Abstract: A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.Type: GrantFiled: January 19, 2010Date of Patent: November 5, 2013Assignee: pSivida US, Inc.Inventors: Hong Guo, Paul Ashton
-
Patent number: 8569272Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.Type: GrantFiled: July 11, 2008Date of Patent: October 29, 2013Assignee: Allergan, Inc.Inventors: Robert T. Lyons, James N. Chang, John T. Trogden, Scott M. Whitcup
-
Patent number: 8563026Abstract: Multilayer protein films are provided, which comprise native bacteriorhodopsin and/or specialized bacteriorhodopsin mutants as the photoactive element. Also provided are artificial subretinal and epiretinal implants carrying such bacteriorhodopsin films, as well as methods for making and using the same, for example, to treat retinal diseases and conditions.Type: GrantFiled: March 5, 2010Date of Patent: October 22, 2013Assignee: University of ConnecticutInventors: Robert R. Birge, Megan Nollenberger, Matthew Ranaghan, Daniel J. Sandberg, Nicole Wagner
-
Patent number: 8563027Abstract: An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline.Type: GrantFiled: February 26, 2013Date of Patent: October 22, 2013Assignee: Incept, LLCInventors: Peter Jarrett, Michael Bassett, Charles D. Blizzard, Amarpreet S. Sawhney
-
Publication number: 20130273136Abstract: A drug delivery system for delivering a drug at a sustained constant rate for a long period, which can be transplanted into an affected part safely and in a simple manner and can deliver a drug to the affected part for a long period. A sustained drug delivery system in which an implant is implanted into a body, wherein the implant is a PEG capsule comprising a box-shaped PEG and a porous PEG sheet.Type: ApplicationFiled: June 4, 2013Publication date: October 17, 2013Inventors: Toshiaki ABE, Nobuhiro NAGAI, Hirokazu KAJI, Takeaki KAWASHIMA, Matsuhiko NISHIZAWA, Koji NISHIDA
-
Publication number: 20130236525Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.Type: ApplicationFiled: March 15, 2013Publication date: September 12, 2013Applicant: Allergan, Inc.Inventors: Glenn T. Huang, Thierry Nivaggioli
-
Patent number: 8529938Abstract: An improved viscoelastic composition useful in the performance of ophthalmic surgical procedures and especially cataract procedures is disclosed. The embodiments of the composition comprise combinations of sodium hyaluronate and chondroitin sulfate and exhibit an improved rheological profile.Type: GrantFiled: September 21, 2010Date of Patent: September 10, 2013Assignee: Alcon Research, Ltd.Inventors: Masoud R. Jafari, Kerry L. Markwardt, Uday Doshi
-
Patent number: 8529927Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.Type: GrantFiled: March 31, 2006Date of Patent: September 10, 2013Assignee: Allergan, Inc.Inventors: James N. Chang, Lon T. Spada, Wendy M. Blanda, Werhner C. Orilla, James A. Burke, Patrick M. Hughes
-
Patent number: 8524779Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.Type: GrantFiled: April 28, 2011Date of Patent: September 3, 2013Assignee: Novagali Pharma SAInventors: Laura Rabinovich-Guilatti, Gregory Lambert, Frederic Lallemand, Betty Philips
-
Patent number: 8486052Abstract: A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient.Type: GrantFiled: December 27, 2010Date of Patent: July 16, 2013Assignee: The Johns Hopkins University School of MedicineInventors: Signe Erickson Varner, Eugene Dejuan, Aaron Christopher Barnes, Terry Harrison Shelley, Michael J. Cooney
-
Patent number: 8486440Abstract: Currently, no efficient, non-invasive methods exist for delivering drugs and/or other therapeutic agents to the interior of the eye to treat or prevent disease or injury. The present invention relates to a novel method that is suitable for the delivery of any therapeutic agent (suitably modified) to the interior of the eye without the need for the penetration of a needle into the eyeball. In a preferred embodiment, it involves an injection into a peripheral vein (or oral administration, or administration by some other eternal or parenteral route) of a solution of inert drug which is trapped in the eye by a magnetic field and activated by radiation once it is in position, so that the active agent is released only where it is needed and can have its therapeutic effect without affecting other tissues or organs. The inert drug may be composed of a biologically compatible magnetic nanoparticle chemically bound to a specially inactivated (caged) form of the drug to be delivered and to a luminescent marker.Type: GrantFiled: January 22, 2007Date of Patent: July 16, 2013Assignee: Lumemed LimitedInventor: Alan Whitmore
-
Patent number: 8475831Abstract: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met.Type: GrantFiled: December 17, 2004Date of Patent: July 2, 2013Assignee: Osio CorporationInventor: Alberto Osio Sancho
-
Patent number: 8469934Abstract: The present invention is directed to a pulsatile ophthalmic peri-corneal drug delivery device. The device includes an annular body and a mechanism for releasing multiple separate and distinct doses of a therapeutic composition over an extended period of time.Type: GrantFiled: January 25, 2011Date of Patent: June 25, 2013Assignee: Alcon Research, Ltd.Inventors: Alan L. Weiner, Bhagwati P. Kabra
-
Publication number: 20130156841Abstract: A method of treating an ocular disease in a subject using a corticosteroid with reduced incidence of intraocular pressure lowering surgery comprises injecting an intravitreal insert capable of providing a therapeutic effect for an extended period of time. The intravitreal insert delivers sustained sub-microgram levels of corticosteroid.Type: ApplicationFiled: February 1, 2013Publication date: June 20, 2013Applicant: ALIMERA SCIENCES, INC.Inventor: Alimera Sciences, Inc.
-
Patent number: 8465759Abstract: A process for the preparation of a bioadhesive laminate comprising a hot-melt extruded reservoir layer and a hot-melt extruded backing layer is provided. The reservoir layer comprises a thermoplastic bioadhesive composition containing an active agent. An active agent-containing thermoplastic bioadhesive hydrophilic composition is hot-melt coextruded with a hydrophobic composition to form at least a bi-layered laminate. The hydrophilic composition and the hydrophobic composition have at least one polymer in common. In addition, the melt flow index of the hydrophobic composition is within 50% of the melt flow index of the hydrophilic composition. As a result, the laminate has a uniform transverse cross-section and/or a uniform longitudinal cross-section throughout a major of the length of the laminate. Moreover, when the laminate is divided into unit doses of approximately the same size, they have a high degree of content uniformity with respect to the active agent(s) present therein.Type: GrantFiled: March 22, 2007Date of Patent: June 18, 2013Assignee: Auxilium US Holdings, LLCInventors: Michael M. Crowley, Justin M. Keen, John J. Koleng, Feng Zhang
-
Publication number: 20130142858Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.Type: ApplicationFiled: May 17, 2011Publication date: June 6, 2013Applicant: Aerie Pharmaceuticals, Inc.Inventors: Casey Kopczynski, Cheng-Wen Lin, Chris Sutay
-
Patent number: 8455572Abstract: This invention relates to the fields of polymer chemistry, materials science and ophthalmology. More particularly it relates to optical components and method(s) of preparing same from hydrophobic acrylic (HA) monomer(s) that exhibit reduced or eliminated glistenings when implanted in a patient's eye. The method of this invention uses a mixture of one or more low temperature initiators (LTI) combined with one or more high temperature initiators (HTI), to polymerize one or more HA monomers to produce an optical HA polymer which, when used to manufacture an optical component and implanted as with an intraocular lens (IOL), exhibit reduced glistenings to the patient.Type: GrantFiled: January 31, 2011Date of Patent: June 4, 2013Assignee: Key Medical Technologies, Inc.Inventor: Khalid Mentak
-
Patent number: 8454691Abstract: A surgical procedure is described for the restoration of eyelid function in individuals suffering from ptosis or upper eyelid droop syndrome that makes a patient unable to voluntarily fully raise an eyelid. The surgical procedure includes implantation and suturing of eye drop (pH) activated and actuated fibrous contractile and expansive artificial muscles such as pH active hydrogels of polyacrylonitrile (PAN) artificial muscles that are surgically implanted and sutured under the superior palpebral conjunctiva in a serpentine parallel configuration with respect to the tarsal (meibomian) glands of the upper eyelid and anchored to the tissues of superior fornix.Type: GrantFiled: October 26, 2009Date of Patent: June 4, 2013Inventors: Mohsen Shahinpoor, David Soltanpour
-
Patent number: 8440217Abstract: A contact lens product, a method and system for forming the contact lens product, and a method of using the contact lens product. The contact lens product includes a soft disposable contact lens loaded with a drug and the carriers which carry the drug. The lens has a mechanical and optical structure formed by the core polymer included within the lens. The contact lens product is configured to have the drug released from its carrier continuously into an eye of a mammal while the contact lens product is adhered to the eye of the mammal during a continuous period of time, the drug being configured to treat or prevent at least one adverse condition of the eye of the mammal during the continuous period of time. The mammal may be a human being or a veterinary animal.Type: GrantFiled: June 15, 2005Date of Patent: May 14, 2013Inventors: Mawaheb M. El-Naggar, Shaker A. Mousa
-
Publication number: 20130101658Abstract: A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.Type: ApplicationFiled: October 4, 2012Publication date: April 25, 2013Applicant: QLT INC.Inventor: QLT INC.
-
Publication number: 20130101657Abstract: Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.Type: ApplicationFiled: September 26, 2012Publication date: April 25, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: The Johns Hopkins University
-
Patent number: 8414911Abstract: The disclosure concerns altering the mechanical and/or chemical property of a body tissue, particularly an ocular tissue. In specific cases, it concerns altering or stabilizing the shape of the cornea, such as in a subject suffering or at risk for ectasia or keratoconus. In other specific cases, it concerns strengthening the sclera in a subject suffering or at risk for myopia. The invention employs light irradiation of a photoactivatable compound, such as one that applies crosslinking to the tissue, for example.Type: GrantFiled: October 24, 2007Date of Patent: April 9, 2013Assignees: The Regents of the University of California, California Institute of TechnologyInventors: Matthew S. Mattson, Julia A. Kornfield, Daniel M. Schwartz, Robert K. Maloney, Robert H. Grubbs
-
Patent number: 8409606Abstract: An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline.Type: GrantFiled: February 12, 2010Date of Patent: April 2, 2013Assignee: Incept, LLCInventors: Amarpreet S. Sawhney, Peter Jarrett, Michael Bassett, Charles Blizzard
-
Patent number: 8404269Abstract: A surgical device and method of making and using the same for implantation in a body of a mammal. One preferred device is prepared to include an elongated member. A region includes a pharmaceutical agent and a bioerodible material, a biodegradable material a bioavailable material or a mixture thereof.Type: GrantFiled: April 9, 2004Date of Patent: March 26, 2013Inventors: Michael Snyder, Eric M. Dobrusin
-
Patent number: 8404270Abstract: A method of treating an ocular disease in a subject using a corticosteroid with reduced incidence of intraocular pressure lowering surgery comprises injecting an intravitreal insert capable of providing a therapeutic effect for an extended period of time. The intravitreal insert delivers sustained sub-microgram levels of corticosteroid.Type: GrantFiled: December 21, 2010Date of Patent: March 26, 2013Assignee: Alimera Sciences, Inc.Inventor: Ken Green
-
Patent number: 8404265Abstract: An appliance for the delivery of at least one bioactive agent to the eye has at least one diffusion attenuator within a hydrophilic or silicone-hydrogel contact lens. The bioactive agent can be a drug or a nutraceutical. The diffusion attenuator can be a plurality of solid particles or phase separated liquid aggregates within at least one continuous phase of the lens where the diffusion attenuators promote a tortuous path for the diffusion of the bioactive agent to mediate the rate by which the bioactive agent diffuses from the contact lens. The diffusion attenuator can be homogeneously dispersed throughout at least one continuous phase of the lens to modify the diffusivity of the bioactive agent through that phase. The diffusion attenuator can have little or no affinity for the bioactive agent or can be miscible with the bioactive agent. The diffusion attenuator can be incorporated while forming the contact lens by polymerization of a monomer mixture containing the diffusion attenuator.Type: GrantFiled: July 22, 2010Date of Patent: March 26, 2013Assignee: University of Florida Research Foundation, Inc.Inventors: Anuj Chauhan, Jinah Kim
-
Patent number: 8399751Abstract: The invention relates to imparting photoreactivity to target cells, e.g., retinal cells, by introducing photoresponsive functional abiotic nanosystems (FANs), nanometer-scale semiconductor/metal or semiconductor/semiconductor hetero-junctions that in this case include a photovoltaic effect. The invention further provides methods of making and using FANs, where the hetero-junctions bear surface functionalization that localizes them in cell membranes. Illumination of these hetero-junctions incorporated in cell membranes generates photovoltages that depolarize the membranes, such as those of nerve cells, in which FANs photogenerate action potentials. Incorporating FANs into the cells of a retina with damaged photoreceptor cells reintroduces photoresponsiveness to the retina, so that light creates action potentials that the brain interprets as sight.Type: GrantFiled: June 12, 2008Date of Patent: March 19, 2013Assignee: University of Southern CaliforniaInventors: Siyuan Lu, Anupam Madhukar, Mark S. Humayun
-
Patent number: 8399005Abstract: The present invention is directed to compositions comprising at least one nitric oxide donor and at least one second therapeutically active agent with antimicrobial or wound healing capability. In one embodiment, the nitric oxide donor is a nanoparticle which is designed to control for the amount and duration of release of nitric oxide. The nanoparticle may further comprise the additional therapeutically active agent. The composition is useful for enhancing wound healing and for treating and preventing microbial infection. In one embodiment, the composition is directed toward reducing oral bacteria or dental plaque. The combination of one or more nitric oxide donors and one or more additional therapeutically active agent results in unexpected synergistic effects, wherein both the antimicrobial efficacy of the nitric oxide and the antimicrobial or wound healing efficacy of the second therapeutically active agent are enhanced.Type: GrantFiled: October 10, 2008Date of Patent: March 19, 2013Assignee: University of North Carolina at Chapel HillInventors: Mark H. Schoenfisch, Evan M. Hetrick, Nathan A. Stasko, C. Bryce Johnson
-
Patent number: 8377464Abstract: This invention describes the use of polymerizable surfactants as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc.Type: GrantFiled: February 27, 2012Date of Patent: February 19, 2013Assignee: Bausch & Lomb IncorporatedInventors: Jeffrey G. Linhardt, Daniel M. Ammon, Jr., Joseph C. Salamone, Daniel J. Hook
-
Publication number: 20130017243Abstract: The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.Type: ApplicationFiled: April 5, 2011Publication date: January 17, 2013Applicant: ALLERGAN, INC.Inventors: Ruiwen Shi, Patrick M. Hughes, James A. Burke, Michael R. Robinson, Hui Liu
-
Publication number: 20130017244Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.Type: ApplicationFiled: September 13, 2012Publication date: January 17, 2013Applicant: Allergan, Inc.Inventors: Glenn T. Huang, Thïerry Nivaggioli
-
Patent number: 8343942Abstract: Described herein are methods for treating interstitial cystitis in a subject comprising administering to the subject an effective amount of a compound which is a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with an unsubstituted alkyl group or fluoroalkyl group.Type: GrantFiled: March 23, 2011Date of Patent: January 1, 2013Assignee: University of Utah Research FoundationInventors: Siam Oottamasathien, Wanjian Jia, Glenn D. Prestwich, Lindsi McCoard
-
Patent number: 8337898Abstract: The invention provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of human carbonic anhydrase II comprises 4-carboxybenzene sulfonamide. The disclosed composition is useful in treatment of glaucoma.Type: GrantFiled: June 7, 2011Date of Patent: December 25, 2012Assignee: University of Central Florida Research Foundation, Inc.Inventors: Sudipta Seal, Swanand D. Patil, Manas K. Haldar, Sanku Malik
-
Patent number: 8333726Abstract: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.Type: GrantFiled: September 8, 2008Date of Patent: December 18, 2012Assignee: QLT Inc.Inventors: Alan R. Rapacki, Valery Rubinchik, John B. Holds, Sylvie Sim, Danny Shen
-
Patent number: 8329673Abstract: Described herein are alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated and alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including use for ocular or ophthalmic treatment.Type: GrantFiled: November 23, 2011Date of Patent: December 11, 2012Assignee: University of Utah Research FoundationInventors: Glenn D. Prestwich, Jianxing Zhang, Thomas P. Kennedy, Narayanam V. Rao
-
Patent number: 8313754Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.Type: GrantFiled: April 11, 2011Date of Patent: November 20, 2012Assignee: Novartis AGInventors: Masood A. Chowhan, Huagang Chen
-
Patent number: 8313763Abstract: The present invention relates to a rapamycin sustained release delivery system for treatment of diseases responsive to rapamycin. The sustained release delivery system of the invention includes a flowable composition containing rapamycin or a rapamycin derivative, which is capable of providing an implant containing the rapamycin or derivative thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid and rapamycin or a rapamycin derivative.Type: GrantFiled: February 15, 2007Date of Patent: November 20, 2012Assignee: Tolmar Therapeutics, Inc.Inventors: Philippe Maria Clotaire Margaron, Eric Dadey, Christopher M. Lindemann, Ruihong Li
-
Patent number: 8298568Abstract: A well tolerated oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs, wherein the emulsion particles have a net positive charge and comprises 0.001 to 0.1% of a cationic agent, 0 to 1% of a non ionic surfactant and 0 to 0.5% of an anionic surfactant.Type: GrantFiled: November 18, 2004Date of Patent: October 30, 2012Assignee: Novagali Pharma SAInventors: Séverine Bague, Betty Philips, Jean-Sébastien Garrigue, Laura Rabinovich-Guilatt, Gregory Lambert
-
Patent number: 8298569Abstract: Ophthalmic oil-in-water emulsions, which comprises colloid particles having an oily core surrounded by an interfacial film, the emulsion comprising an 10 immunosuppressive agent, an oil, preferably at least 50% of which being MCT, and tyloxapol. Use of such an emulsion for the manufacture of medicament for treatment of eye conditions, particularly of dry eye diseases.Type: GrantFiled: October 10, 2005Date of Patent: October 30, 2012Assignee: Novagali Pharma SAInventors: Betty Philips, Severine Bague, Laura Rabinovich-Guilatt, Gregory Lambert
-
Patent number: 8277834Abstract: The present invention is a method of manufacturing an eye lens material having a process in which a phosphorylcholine group-containing chemical compound represented by the following formula (1) is reacted and covalently bonded onto the surface of an eye lens material wherein a chemical compound having an end amino group is introduced to said eye lens material and then the chemical compound represented by the following formula (2) or (3) is introduced through said chemical compound having an end amino group. The object of the present invention is to provide a method of manufacturing a contact lens that prevents protein adsorption.Type: GrantFiled: May 18, 2005Date of Patent: October 2, 2012Assignees: Shiseido Company, Ltd.Inventors: Yukimitsu Suda, Kazuyuki Miyazawa, Kazuhiko Ishihara
-
Patent number: 8257730Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.Type: GrantFiled: April 29, 2005Date of Patent: September 4, 2012Assignee: Allergan, Inc.Inventors: Glenn T. Huang, Thierry Nivaggioli, Lon T. Spada, Hiroshi Sugimoto, Wendy M Blanda, James N. Chang, Orest Olejnik
-
Patent number: 8257749Abstract: A process reduces the insect, arthropod or pest content in land mass by providing molecular iodine in the land mass in a concentration in aqueous material in the land mass of at least 10 parts per million. The molecular iodine may be added in gaseous or liquid or solid state, and may be formed in situ in the land mass using available water in the reaction.Type: GrantFiled: January 31, 2008Date of Patent: September 4, 2012Assignee: Biolargo Life Technologies, IncorporatedInventor: Kenneth R. Code